Closed Loop Medicine Brings Personalised GLP-1 Dosing to the U.S with WeDosify

Closed Loop Medicine Ltd (CLM), a UK-based leader in personalised pharmaceutical dosing, has announced the U.S. launch of WeDosify, its first commercially available product. The platform is designed to help clinicians improve long-term adherence to GLP-1 therapies by tailoring dose escalation and maintenance to each patient’s tolerability and treatment goals.

Global demand for anti-obesity medicines continues to accelerate, with the market expected to grow from US$30 billion in 2024 to US$100 billion by 2030. Yet, despite their efficacy, up to 44% of patients stop GLP-1 therapy within six months, a figure that rises to 60% within a year, largely because of dose-related gastrointestinal side effects such as nausea and diarrhoea, as well as a lack of structured support for long-term use.

WeDosify aims to address this problem by presenting data-driven, individualised dosing options for clinical review, updating recommendations in real time as a patient responds to treatment. The technology is informed by 29 studies and more than 15,000 patient profiles, underpinned by pharmacokinetic/pharmacodynamic modelling.

A recent survey found that 91% of GLP-1 patients would be more likely to stay on treatment if supported by WeDosify. One respondent explained: “Having data helps you make personalized decisions and makes you more engaged with your weight loss journey.”

Clinicians are already adopting the tool. Dr. Neese, from Amarillo Premier Research in Texas, commented: “I am delighted to have the opportunity to share WeDosify with my patients. It will enable me to work with each patient to determine a course of action that is genuinely personal to them, helping them to achieve lasting weight loss.”

Kate Woolland, CEO of CLM, positioned the launch as a milestone: “WeDosify is the first product that offers genuinely personalized recommendations which update in real time to reflect how the patient is responding to the drug. For the first time, patients can see what their weight loss journey might look like and work alongside their clinician to make decisions about their health. This is a genuine gamechanger.”

The timing is significant. Regulatory efforts such as the Right Drug Dose Now Act and the White House’s HTI-4 digital health commitment highlight growing emphasis on precision prescribing and reducing adverse drug events. Meanwhile, drug developers are increasingly focused on balancing GLP-1 efficacy with tolerability; slow, individualised titration schedules have been shown to improve patient outcomes in recent clinical studies.

By tackling adherence, CLM hopes WeDosify will extend the undoubted benefits of GLP-1 therapy to more patients for longer, potentially setting a new standard for how weight-loss medicines are used in practice.